Bortezomib is a proteasome inhibitor for the treatment of relapsed/refractory multiple myeloma (MM 
Introduction
Myeloid cell leukemia-1 (Mcl-1) is an antiapoptotic protein in the Bcl-2 family. Among Bcl-2 family members, Mcl-1 distinguishes itself by its ability to oppose several apoptotic stimuli, as well as the presence of polypeptide sequences enriched in proline (P), glutamic acid (E), serine (S) and threonine (T) domains (PEST), which could be responsible for its short half-life (3-4 h). Thus, Mcl-1 is involved in both cell homeostasis and differentiation (Craig, 2002; Opferman, 2006) . Deletion of Mcl-1 prevents embryonic development, since Mcl-1 null embryos fail to survive pre-implantation development and implantation (Rinkenberger et al., 2000) . Mcl-1 is also required for development and maintenance of B and T cells (Opferman et al., 2003) and plays an obligate role in the survival of hematopoietic stem cells (Opferman et al., 2005) . Overexpression of Mcl-1 promotes cell immortalization whereas downregulation induces apoptosis (Zhou et al., 1998; Nijhawan et al., 2003) . This prosurvival function is conferred predominantly by Mcl-1 binding to proapoptotic proteins such as Bak, to form heterodimers and thereby prevent cell death (Leu et al., 2004) . Conversely, release of Bak from its interaction with Mcl-1 induces apoptosis . Interestingly, Mcl-1 is regulated at transcriptional, post-transcriptional and post-translational levels (Craig, 2002; Le Gouill et al., 2004b; Opferman, 2006) . Mcl-1 transcription is upregulated via several cytokines and growth factors via various signaling pathways. At the post-transcriptional level, Mcl-1 (located on chromosome 1q21) undergoes alternative splicing: the junction of the first and third exons, without exon 2, encodes for a 271-amino-acid Mcl-1 short protein, which has a proapoptotic function (Bae et al., 2000) . At the post-translational level, caspase-3 triggers Mcl-1 cleavage with resultant Mcl-1 cleaved forms, some of which have potent proapoptotic functions (Michels et al., 2004; Weng et al., 2005) . Moreover, Mcl-1 is regulated by phosphorylation. For example, oxidative stress triggers Mcl-1 phosphorylation via JNK at serine-121 and threonine-163 resulting in the loss of its antiapoptotic function (Inoshita et al., 2002) . In addition, Mcl-1 is phosphorylated at serine-159 by glycogen synthase kinase-3 and thereby destabilizes Mcl-1 protein and induces apoptosis (Maurer et al., 2006) .
Multiple myeloma (MM) is a clonal B-cell malignancy characterized by the accumulation of malignant plasma cells within the bone marrow (BM) (Bataille and Harousseau, 1997) . Despite intensive therapy including autologous hematopoietic stem cell support, MM remains incurable. Specific inhibition of Mcl-1, but not of Bcl-2 or Bcl-XL, using antisense oligonucleotide or Mcl-1 small interfering RNA (siRNA) induces apoptosis of MM cells, confirming the crucial antiapoptotic role of Mcl-1 in malignant plasma cells (Derenne et al., 2002; Zhang et al., 2002; Le Gouill et al., 2004b) . Moreover, interleukin-6 (IL-6) and vascular endothelial growth factor upregulate Mcl-1 expression in MM cells and thereby protect against apoptosis (Puthier et al., 1999; Le Gouill et al., 2004a) . Mcl-1 is therefore a potential novel therapeutic target in MM.
The proteasome inhibitor Bortezomib (formerly PS-341; Velcade, Millenium Pharmaceuticals Inc., Cambridge, MA, USA), a novel dipeptide boromic acid, has been Food and Drug Administration (FDA) approved in May 2003 for treatment of relapsed or refractory MM and is currently under clinical investigation as front-line therapy (Richardson et al., 2003) . Bortezomib has various mechanisms of action against MM cells including induction of apoptosis, inhibition of nuclear factor-kB activation, triggering of caspasedependent cleavage of gp130, downregulation of adhesion molecule expression on MM cells and BM stromal cells, inhibition of angiogenesis and decreasing secretion of survival and proliferative cytokines (Hideshima et al., 2001 (Hideshima et al., , 2003a LeBlanc et al., 2002; Podar et al., 2004b; Roccaro et al., 2006) . However, mechanisms mediating Bortezomib resistance are not fully understood. Here, we add another facet to the anti-MM functions of Bortezomib by characterizing the role of -cleaved protein in Bortezomib-induced cell apoptosis using both MM cells as well as Mcl-1-lacking murine embryonic fibroblasts (MEFs). On the basis of our data, we recommend the combination of Bortezomib with agents that induce MM cell death independent of Mcl-1.
Results
Bortezomib reduces cell viability and induces Mcl-1 cleavage associated with cleavage of caspase -3, -8, -9 and PARP Using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, we first determined the affects of both Bortezomib and doxorubicin on MM.1S cell viability. Cells were cultured with or without various doses of Bortezomib or doxorubicin for 48 h. Treatment with Bortezomib ( Figure 1a ) and doxorubicin (Figure 1b) decreases MM.1S viability in a dose-dependent manner. The median inhibitory concentration (IC 50 ) was 4 and 45 nM for Bortezomib and doxorubicin, respectively.
Next, we used western blot analysis to determine whether Bortezomib and doxorubicin treatment modifies Mcl-1, caspase-3, -8, -9 and poly (ADP) ribose polymerase (PARP), as well as Bcl-2 expression in MM.1S cells in a dose-and/or time-dependent fashion. Specifically, our results show that high-dose Bortezomib (10 nM) induces Mcl-1 cleavage only after 6 h, resulting in the accumulation of a 28 kDa Mcl-1-cleaved product and cleavage of caspase-3, -8, -9 and PARP. Importantly, Mcl-1 downregulation and cleavage was also observed at concentrations as low as 2.5 nM after longer periods of Bortezomib treatment (24 h). In contrast to Mcl-1, no modification of Bcl-2 was observed at any time point (Figure 2a) . Moreover, although high-dose treatment with doxorubicin induced Mcl-1 downregulation in MM.1S cells, we did not observe any accumulation of the Mcl-1-cleaved protein (Figure 2b ). We hypothesize that this late effect reflects an apoptotic shutdown of the MM cell and that doxorubicin-induced decrease of Mcl-1 may be either due to the short half-life of Mcl-1 mRNA or reduced Mcl-1 promoter activity. However, PARP cleavage, indicative for doxorubicin-induced cell death, was observed also at lower doses of doxorubicin. Taken together, these results demonstrate that low-dose Bortezomib, but not doxorubicin, induces early generation of a 28 kDa Mcl-1 fragment associated with cleavage of caspase-3, -8, -9 and PARP.
Bortezomib-induced fragmentation of Mcl-1 is caspase dependent To investigate the potential role of caspases in Bortezomib-induced Mcl-1 cleavage, MM.1S cells were preincubated with pan-caspase inhibitor (z-VAD-fmk, z-Val-Ala-Asp(OCH 3 )-Fluoromethylketone), caspase-9 inhibitor (z-LEHD-fmk, z-Leu-Glu(OMe)-His-Asp(OMe)-Fluoromethylketone) and caspase-8 inhibitor (z-IETDfmk, z-lle-Glu-Thr-Asp-Fluoromethylketone) (3 h) and then treated with Bortezomib (6 h). Pretreatment with the pan-caspase inhibitor as well as with the caspase-9 inhibitor, and to a lesser extent with the caspase-8 inhibitor, blocked Bortezomib-induced Mcl-1 cleavage and thus the appearance of the 28 kDa Mcl-1-cleaved protein (Figure 3a ).
Bortezomib generates a previously reported 28 kDa
Mcl-1 fragment The generation of a 28 kDa cleaved Mcl-1 product was previously reported in several cisplatin-treated malignant B cells. Importantly, this fragment was identified as and functionally linked to proapoptosis (Michels et al., 2004) . We therefore hypothesized that the 28 kDa Mcl-1-fragment generated in Bortezomibtreated MM cells is identical with and also contributes to Bortezomib-induced MM cell death. Indeed, the Bortezomib- Figure 6a ) and RPMI cells (data not shown). In contrast, no fragment was generated in the INA-6 MM cell line treated with Bortezomib (data not shown). Previous data show that proteasome inhibitors such as Bortezomib induce increased expression of BH3-only protein NOXA in several tumor cells including melanoma, mantle-cell lymphoma and MM. Importantly, NOXA upregulation is associated with tumor cell apoptosis (Qin et al., 2005; Perez-Galan et al., 2006) . Indeed, in contrast to other BH3-only proteins, which exhibit promiscuous binding, NOXA only binds Mcl-1 and A1 . Mcl-1 binding to NOXA induces apoptosis both by releasing Bak from its interaction with Mcl-1 and by promoting Mcl-1 degradation . Consistent with these data, we observed that Bortezomib-induced cleavage of Mcl-1 was accompanied by expressional upregulation of NOXA in all MM cell lines (Figure 6a Lack of Mcl-1 protects against Bortezomib-but not doxorubicin-and melphalan-induced PARP and caspase-3 cleavage Finally, the mechanism whereby Mcl-1 mediates Bortezomib-induced apoptosis was investigated. We therefore compared caspase-3, -9 and PARP cleavage triggered by (Figure 8 ). Taken together, these experiments demonstrate that Bortezomib induces Mcl-1-dependent apoptotic signaling events, whereas doxorubicin and melphalan trigger Mcl-1-independent apoptotic cascades.
Discussion
Bortezomib is a proteasome inhibitor for the treatment of relapsed/refractory MM (Chauhan et al., 2005) . However, the majority of patients with relapsed or refractory MM does not respond, and occurrence of resistance is common. Mechanisms conferring Bortezomib resistance are undefined. Mcl-1 is an antiapoptotic protein, originally identified as an 'early induction' gene during myeloblastic leukemic cell differentiation (Kozopas et al., 1993) , which protects tumor cells against spontaneous and chemotherapy-induced apoptosis. 
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Mcl-1 forms heterodimers with proapoptotic BH3-onlyproteins Bim and NOXA, or with Bak, thereby preventing cytochrome c release and caspase activation.
Owing to its binding with BH3-only protein and short half-life, Mcl-1 is therefore an early checkpoint regulating the apoptotic/survival balance (Opferman et al., 2003; Han et al., 2004; Willis et al., 2005) . In MM, specific downregulation of Mcl-1 in tumor cells induces Mcl-1 is highly and tightly regulated. Mcl-1, like other Bcl-2 family members, is subjected to post-translational regulation, including phosphorylation and cleavage. Specifically, extracellular signal-regulated kinase (ERK)-dependent or -independent pathways mediate phosphorylation of Mcl-1. Taxol-triggered ERK-independent Mcl-1 phosphorylation promotes cell death, whereas 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-triggered ERK-dependent Mcl-1 phosphorylation promotes cell viability via slowing the cell cycle and reducing Mcl-1 turnover (Domina et al., 2000 (Domina et al., , 2004 . At the post-translational level, Mcl-1 is cleaved (Michels et al., 2004 ) have lost the BH4 domain and are structurally similar to Bax, a proapoptotic protein of the Bcl-2 family. Indeed, Michels et al. (2004) have demonstrated that Mcl-1 128-
350
-cleaved protein triggered by cisplatin accumulates in Akata6 B-lymphoma cells, and that its overexpression induces apoptosis. In Jurkat T cells, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers Mcl-1 cleavage through caspase-3 activation and conversely, mutations in Mcl-1-cleaved sites protect against TRAIL-induced apoptosis (Weng et al., 2005) . Moreover, the C-terminal Mcl-1 128-350 -cleaved product mediates TRAIL-induced apoptosis, by acting as a proapoptotic protein cooperating with tBid and Bak to regulate mitochondrial apoptotic events.
Here, we demonstrate that Bortezomib, but not doxorubicin, triggers caspase-3, -8 and -9 dependent generation of a previously reported 28 kDa Mcl-1 fragment, , in several MM cell lines including MM.1S cells. However, whether caspase-8 processing results in active caspase-8 is controversial to date. We were unable to detect other Mcl-1-cleaved products, since the epitope targeted by S-19 antibody is not present in the Mcl-1 -cleaved product (Michels et al., 2004; Weng et al., 2005 . Consistent with these data, our results show that Bortezomib induces apoptosis dependent on Mcl-1. We hypothesize that combined neutralization of both Mcl-1 and Bcl-XL drive efficient Bak-mediated apoptosis . Ongoing experiments in MM are evaluating this hypothesis.
Our Hideshima et al. (2001) , Chauhan et al. (2004) Bortezomib induces apoptosis by triggering mitochondrial events leading to caspase activation. Indeed, DHL-4 cell line expresses low levels of caspase-3 and -8, which confers resistance to Bortezomib. In contrast, doxorubicin induces apoptosis through activation of several apoptotic pathways, including DNA damage through topoisomerase II inhibition and free radical production (Gewirtz, 1999; Hurley, 2002) . Indeed, doxorubicin-triggered caspase-3 activity is due to stress response (SR)-mediated stress (Jang et al., 2004) . The comparison therefore shows that Bortezomib and doxorubicin induce distinct Mcl-1-dependent and -independent apoptotic pathways.
In conclusion, our study demonstrates that lack of Mcl-1 and Mcl-1 128-350 fragment confers resistance to Bortezomib and protects against Bortezomib-induced (Pei et al., 2004) and Bortezomib and doxorubicin with seliciclib, a small molecule cyclin-dependent kinase inhibitor (Raje et al., 2005) . Recently, Orlowski et al. (2005) have combined these two drugs and demonstrated remarkably activity in patients with relapsed or refractory hematologic malignancies, supporting the potential utility of this therapeutic strategy.
Materials and methods
Cells and cell culture MEF cell lines Mcl-1 wt/wt and Mcl-1 D/null were generated by SV40 large T transformation followed by Tat-Cre-mediated deletion. Single cell clones were selected and then grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 10 mg streptomycin and 2 mM L-glutamine, 2-mercapto-ethanol (Sigma, St Louis, MO, USA) and minimum essential meduium (MEM) non-essential amino acid (Gibco, Grand Island, NY, USA) to be used from early passages. Both Mcl-1 wt/wt and Mcl-1 D/null were extensively characterized as being hypersensitive to various death stimuli with restorable resistance upon re-expression of Mcl-1 (Opferman et al., 2003) . The human MM cell line MM.1S was maintained in RPMI-1640 medium with 2 mM L-glutamine (Mediatech, Cellgro, AK, USA) supplemented with 10% heatinactivated FBS, 100 U/ml penicillin and 10 mg streptomycin (Mediatech).
Cell viability assays
Cell viability was assessed by MTT (Chemicon International, Temecula, CA, USA) assay, according to manufacturer's instructions (Roche Molecular Biochemicals, Indianapolis, IN, USA). Cells were seeded in 96-well plates. Cell viability was evaluated as described previously and survival estimated relative to untreated controls (Chauhan et al., 1996) .
Cell-cycle analysis
For cell-cycle analysis, DNA was stained with propidium iodide as described previously . Apoptotic cells were detected as a subdiploid peak, as described by Zamai et al. (1993) . Flow cytometry was analysed using Cytomics RXP program (Beckman Coulter, Inc., Fullerton, CA, USA).
Cell lysis and western blot Cells were treated with various concentrations of Bortezomib (Millenium Pharmaceuticals), doxorubicin or melphalan, washed two times with 1 Â phosphate-buffered saline, and suspended in lysis buffer (10 mM Tris, pH 7.6, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM sodium vanadate, 1 mM N-phenylmethyl sulfonyl fluoride and 2 mg/ml aprotinin). After 10 min on ice, lysates were cleared by centrifugation at 13 000 g/min for 30 min at 41C; and were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, before electrophoretic transfer onto Hybond C supermembrane (Amersham, Arlington Heights, IL, USA). The blots were probed overnight with anti-human Mcl-1, Bcl-2, actin, caspase-3, -8, Bim and NOXA (Santa Cruz Biotechnology; Santa Cruz, CA, USA); anti-murine Mcl-1 (Rockland, Gilbertsville, PA, USA); anti-actin (Santa Cruz Biotechnology); and anti-PARP (Cell Signaling Technology, Beverly, MA, USA) antibodies. After washing, blots were incubated with secondary antibodies, followed by exposure to enhanced chemiluminescence substrate. 1-127 were kindly provided by Dr G Packham and transfected using Nucleofactor Kit V according to the manufacturer's instructions (Amaxa Biosystems, Cologne, Germany) (Michels et al., 2004) . For Mcl-1-specific knockdown experiments, MM.1S cells were transiently transfected with 200 nM of siRNA SMARTpool for Mcl-1, siGLO Green or non-specific control duplexes (pool of four; Upstate Cell Signalling Solutions, Charlottesville, VA, USA/Dharmacon RNA Technologies, Lafayette, CO, USA) as described previously (Le Gouill et al., 2004a) .
